TY  - JOUR
AU  - Ludwig, Gerd
AU  - Mojić, Marija
AU  - Bulatović, Mirna
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Steinborn, Dirk
AU  - Kaluđerović, Goran N
PY  - 2016
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3827
AB  - In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1-4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5-8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1-4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug's tumoricidal action on 8505C cell line.
PB  - Sharjah: Bentham Science Publishers
T2  - Anti-Cancer Agents in Medicinal Chemistry
T1  - Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
IS  - 11
VL  - 16
DO  - 10.2174/1871520615666151029100749
SP  - 1455
EP  - 1460
ER  - 

@article{
author = "Ludwig, Gerd and Mojić, Marija and Bulatović, Mirna and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Steinborn, Dirk and Kaluđerović, Goran N",
year = "2016",
abstract = "In vitro studies with the ruthenium(II) and analogous iridium(III) complexes [Ru(η6- p-cymene)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}], [Ru(η6-p-cymene)Cl{Ph2PCH2CH2CH2S(O)xPh- κP,κS}][PF6] (1-4), [Ir(η5-C5Me5)Cl2{Ph2PCH2CH2CH2S(O)xPh-κP}] and [Ir(η5-C5Me5)Cl{Ph2 PCH2CH2CH2S(O)xPh-κP,κS}][PF6] (5-8; x = 0, 1) revealed the high selectivity toward the 8505C, A253, MCF-7, SW480 and 518A2 cancer cell lines. Thus, the cationic ruthenium complex 4 proved to be the most selective one. In case of the neutral and cationic ruthenium complexes 1-4 the caspase-dependent apoptotic cell death was proven as the main cause of the drug's tumoricidal action on 8505C cell line.",
publisher = "Sharjah: Bentham Science Publishers",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
title = "Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes",
number = "11",
volume = "16",
doi = "10.2174/1871520615666151029100749",
pages = "1455-1460"
}

Ludwig, G., Mojić, M., Bulatović, M., Mijatović, S., Maksimović-Ivanić, D., Steinborn, D.,& Kaluđerović, G. N.. (2016). Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes. in Anti-Cancer Agents in Medicinal Chemistry
Sharjah: Bentham Science Publishers., 16(11), 1455-1460.
https://doi.org/10.2174/1871520615666151029100749

Ludwig G, Mojić M, Bulatović M, Mijatović S, Maksimović-Ivanić D, Steinborn D, Kaluđerović GN. Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes. in Anti-Cancer Agents in Medicinal Chemistry. 2016;16(11):1455-1460.
doi:10.2174/1871520615666151029100749 .

Ludwig, Gerd, Mojić, Marija, Bulatović, Mirna, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Steinborn, Dirk, Kaluđerović, Goran N, "Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes" in Anti-Cancer Agents in Medicinal Chemistry, 16, no. 11 (2016):1455-1460,
https://doi.org/10.2174/1871520615666151029100749 . .

TY  - JOUR
AU  - Bulatović, Mirna Z.
AU  - Maksimović-Ivanić, Danijela
AU  - Bensing, Christian
AU  - Gomez-Ruiz, Santiago
AU  - Steinborn, Dirk
AU  - Schmidt, Harry
AU  - Mojić, Marija
AU  - Korac, Aleksandra
AU  - Golic, Igor
AU  - Perez-Quintanilla, Damian
AU  - Momčilović, Miljana
AU  - Mijatović, Sanja
AU  - Kaluđerović, Goran N.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2205
AB  - The strong therapeutic potential of an organotin(IV) compound loaded in
   nanostructured silica (SBA-15pSn) is demonstrated: B16 melanoma tumor
   growth in syngeneic C57BL/6 mice is almost completely abolished. In
   contrast to apoptosis as the basic mechanism of the anticancer action of
   numerous chemotherapeutics, the important advantage of this SBA-15pSn
   mesoporous material is the induction of cell differentiation, an effect
   unknown for metal-based drugs and nanomaterials alone. This
   non-aggressive mode of drug action is highly efficient against cancer
   cells but is in the concentration range used nontoxic for normal tissue.
   JNK (Jun-amino-terminal kinase)-independent apoptosis accompanied by the
   development of the melanocyte-like nonproliferative phenotype of
   survived cells indicates the extraordinary potential of SBA-15pSn to
   suppress tumor growth without undesirable compensatory proliferation of
   malignant cells in response to neighboring cell death.
T2  - Angewandte Chemie-International Edition
T1  - Organotin(IV)-Loaded Mesoporous Silica as a Biocompatible Strategy in
 Cancer Treatment
IS  - 23
VL  - 53
DO  - 10.1002/anie.201400763
SP  - 5982
EP  - 5987
ER  - 

@article{
author = "Bulatović, Mirna Z. and Maksimović-Ivanić, Danijela and Bensing, Christian and Gomez-Ruiz, Santiago and Steinborn, Dirk and Schmidt, Harry and Mojić, Marija and Korac, Aleksandra and Golic, Igor and Perez-Quintanilla, Damian and Momčilović, Miljana and Mijatović, Sanja and Kaluđerović, Goran N.",
year = "2014",
abstract = "The strong therapeutic potential of an organotin(IV) compound loaded in
   nanostructured silica (SBA-15pSn) is demonstrated: B16 melanoma tumor
   growth in syngeneic C57BL/6 mice is almost completely abolished. In
   contrast to apoptosis as the basic mechanism of the anticancer action of
   numerous chemotherapeutics, the important advantage of this SBA-15pSn
   mesoporous material is the induction of cell differentiation, an effect
   unknown for metal-based drugs and nanomaterials alone. This
   non-aggressive mode of drug action is highly efficient against cancer
   cells but is in the concentration range used nontoxic for normal tissue.
   JNK (Jun-amino-terminal kinase)-independent apoptosis accompanied by the
   development of the melanocyte-like nonproliferative phenotype of
   survived cells indicates the extraordinary potential of SBA-15pSn to
   suppress tumor growth without undesirable compensatory proliferation of
   malignant cells in response to neighboring cell death.",
journal = "Angewandte Chemie-International Edition",
title = "Organotin(IV)-Loaded Mesoporous Silica as a Biocompatible Strategy in
 Cancer Treatment",
number = "23",
volume = "53",
doi = "10.1002/anie.201400763",
pages = "5982-5987"
}

Bulatović, M. Z., Maksimović-Ivanić, D., Bensing, C., Gomez-Ruiz, S., Steinborn, D., Schmidt, H., Mojić, M., Korac, A., Golic, I., Perez-Quintanilla, D., Momčilović, M., Mijatović, S.,& Kaluđerović, G. N.. (2014). Organotin(IV)-Loaded Mesoporous Silica as a Biocompatible Strategy in
 Cancer Treatment. in Angewandte Chemie-International Edition, 53(23), 5982-5987.
https://doi.org/10.1002/anie.201400763

Bulatović MZ, Maksimović-Ivanić D, Bensing C, Gomez-Ruiz S, Steinborn D, Schmidt H, Mojić M, Korac A, Golic I, Perez-Quintanilla D, Momčilović M, Mijatović S, Kaluđerović GN. Organotin(IV)-Loaded Mesoporous Silica as a Biocompatible Strategy in
 Cancer Treatment. in Angewandte Chemie-International Edition. 2014;53(23):5982-5987.
doi:10.1002/anie.201400763 .

Bulatović, Mirna Z., Maksimović-Ivanić, Danijela, Bensing, Christian, Gomez-Ruiz, Santiago, Steinborn, Dirk, Schmidt, Harry, Mojić, Marija, Korac, Aleksandra, Golic, Igor, Perez-Quintanilla, Damian, Momčilović, Miljana, Mijatović, Sanja, Kaluđerović, Goran N., "Organotin(IV)-Loaded Mesoporous Silica as a Biocompatible Strategy in
 Cancer Treatment" in Angewandte Chemie-International Edition, 53, no. 23 (2014):5982-5987,
https://doi.org/10.1002/anie.201400763 . .

TY  - JOUR
AU  - Ludwig, Gerd
AU  - Randelovic, Ivan
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Bulatović, Mirna Z.
AU  - Miljković, Đorđe
AU  - Korb, Marcus
AU  - Lang, Heinrich
AU  - Steinborn, Dirk
AU  - Kaluđerović, Goran N.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2193
AB  - Iridium(III) complexes of the type
   {[}Ir(eta(5)-C5Me5)Cl-2\{Ph2PCH2-CH2CH2S(O)(x)Ph-kappa P\}] (x=0-2; 1-3)
   and {[}Ir(eta(5)-C5Me5)Cl\{Ph2PCH2-CH2CH2S(O)(x)Ph-kappa P,kappa
   S\}]{[}PF6] (x=0-1; 4 and 5) with 3-(diphenyl-phosphino)propyl phenyl
   sulfide, sulfoxide, and sulfone ligands Ph2PCH2CH2CH2S(O)(x)Ph were
   designed, synthesized, and characterized fully, including X-ray
   diffraction analyses for complexes 3 and 4. In vitro studies against
   human thyroid carcinoma (8505C), submandibular carcinoma (A253), breast
   adenocarcinoma (MCF-7), colon adenocarcinoma (SW480), and melano-ma
   (518A2) cell lines provided evidence for the high biological potential
   of the neutral and cationic iridium(III) complexes. Neutral iridium(III)
   complex 5 proved to be the most active, with IC50 values up to about 0.1
   mu m, representing activities of up to one order of magnitude higher
   than cisplatin. Using 8505C cells, apoptosis was shown to be the main
   mechanism through which complex 5 exerts its tumoricidal action. The
   described iridium(III) complexes represent potential leads in the search
   for novel metal-based anticancer agents.
T2  - Chemmedchem
T1  - Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands
IS  - 7
VL  - 9
DO  - 10.1002/cmdc.201300479
SP  - 1586
EP  - 1593
ER  - 

@article{
author = "Ludwig, Gerd and Randelovic, Ivan and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Bulatović, Mirna Z. and Miljković, Đorđe and Korb, Marcus and Lang, Heinrich and Steinborn, Dirk and Kaluđerović, Goran N.",
year = "2014",
abstract = "Iridium(III) complexes of the type
   {[}Ir(eta(5)-C5Me5)Cl-2\{Ph2PCH2-CH2CH2S(O)(x)Ph-kappa P\}] (x=0-2; 1-3)
   and {[}Ir(eta(5)-C5Me5)Cl\{Ph2PCH2-CH2CH2S(O)(x)Ph-kappa P,kappa
   S\}]{[}PF6] (x=0-1; 4 and 5) with 3-(diphenyl-phosphino)propyl phenyl
   sulfide, sulfoxide, and sulfone ligands Ph2PCH2CH2CH2S(O)(x)Ph were
   designed, synthesized, and characterized fully, including X-ray
   diffraction analyses for complexes 3 and 4. In vitro studies against
   human thyroid carcinoma (8505C), submandibular carcinoma (A253), breast
   adenocarcinoma (MCF-7), colon adenocarcinoma (SW480), and melano-ma
   (518A2) cell lines provided evidence for the high biological potential
   of the neutral and cationic iridium(III) complexes. Neutral iridium(III)
   complex 5 proved to be the most active, with IC50 values up to about 0.1
   mu m, representing activities of up to one order of magnitude higher
   than cisplatin. Using 8505C cells, apoptosis was shown to be the main
   mechanism through which complex 5 exerts its tumoricidal action. The
   described iridium(III) complexes represent potential leads in the search
   for novel metal-based anticancer agents.",
journal = "Chemmedchem",
title = "Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands",
number = "7",
volume = "9",
doi = "10.1002/cmdc.201300479",
pages = "1586-1593"
}

Ludwig, G., Randelovic, I., Maksimović-Ivanić, D., Mijatović, S., Bulatović, M. Z., Miljković, Đ., Korb, M., Lang, H., Steinborn, D.,& Kaluđerović, G. N.. (2014). Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands. in Chemmedchem, 9(7), 1586-1593.
https://doi.org/10.1002/cmdc.201300479

Ludwig G, Randelovic I, Maksimović-Ivanić D, Mijatović S, Bulatović MZ, Miljković Đ, Korb M, Lang H, Steinborn D, Kaluđerović GN. Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands. in Chemmedchem. 2014;9(7):1586-1593.
doi:10.1002/cmdc.201300479 .

Ludwig, Gerd, Randelovic, Ivan, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Bulatović, Mirna Z., Miljković, Đorđe, Korb, Marcus, Lang, Heinrich, Steinborn, Dirk, Kaluđerović, Goran N., "Anticancer Potential of
 (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing
 kappa P and kappa P,kappa S-Coordinated Ph2PCH2CH2CH2S(O)(x)Ph (x=0-2)
 Ligands" in Chemmedchem, 9, no. 7 (2014):1586-1593,
https://doi.org/10.1002/cmdc.201300479 . .

TY  - JOUR
AU  - Ludwig, Gerd
AU  - Mijatović, Sanja
AU  - Ranđelović, Ivan
AU  - Bulatović, Mirna Z.
AU  - Miljković, Đorđe
AU  - Maksimović-Ivanić, Danijela
AU  - Korb, Marcus
AU  - Lang, Heinrich
AU  - Steinborn, Dirk
AU  - Kaluđerović, Goran N.
PY  - 2013
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/948
AB  - Neutral iridium(III) complexes of the type [Ir(eta(5)-C5Me5)Cl-2{Ph2PCH2S(O)(x)Ph-kappa P}] (1-3) with diphenylphosphino-functionalized methyl phenyl sulfides, sulfoxides, and sulfones Ph2PCH2S(O)(x)Ph (x = 0, L1; 1, 12; 2, L3) and the cationic complex [Ir(eta(5)-C5Me5)Cl(Ph2PCH2SPh-kappa P,kappa S}][PF6] (4) were synthesized and fully characterized analytically and spectroscopically. Furthermore, the structure of 2 was determined by X-ray diffraction analysis. The biological potential of the neutral and cationic iridium(III) complexes was tested in vitro against the cell lines 8505C, A253, MCF-7, SW480 and 518A2. Complex [Ir(eta(5)-C5Me5)Cl-2{Ph2PCH2S(O)Ph-kappa P}] (2), with ligand L2 kappa P coordinated containing a pendent sulfinyl group, is the most active one (IC50 values of about 3 mu M), thus, with activities comparable to cisplatin. Complex 2 proved to have an even a higher antiproliferative activity than cisplatin against 8505C and SW480 cell lines, used as a model system of highly anaplastic cancers with low sensitivity to conventional chemotherapeutics such as cisplatin. Additional experiments demonstrated that apoptosis and autophagic cell death contribute to the drug's tumoricidal action. (C) 2013 Elsevier Masson SAS. All rights reserved.
T2  - European Journal of Medicinal Chemistry
T1  - Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands
IS  - null
VL  - 69
SP  - 33
EP  - 222
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_948
ER  - 

@article{
author = "Ludwig, Gerd and Mijatović, Sanja and Ranđelović, Ivan and Bulatović, Mirna Z. and Miljković, Đorđe and Maksimović-Ivanić, Danijela and Korb, Marcus and Lang, Heinrich and Steinborn, Dirk and Kaluđerović, Goran N.",
year = "2013",
abstract = "Neutral iridium(III) complexes of the type [Ir(eta(5)-C5Me5)Cl-2{Ph2PCH2S(O)(x)Ph-kappa P}] (1-3) with diphenylphosphino-functionalized methyl phenyl sulfides, sulfoxides, and sulfones Ph2PCH2S(O)(x)Ph (x = 0, L1; 1, 12; 2, L3) and the cationic complex [Ir(eta(5)-C5Me5)Cl(Ph2PCH2SPh-kappa P,kappa S}][PF6] (4) were synthesized and fully characterized analytically and spectroscopically. Furthermore, the structure of 2 was determined by X-ray diffraction analysis. The biological potential of the neutral and cationic iridium(III) complexes was tested in vitro against the cell lines 8505C, A253, MCF-7, SW480 and 518A2. Complex [Ir(eta(5)-C5Me5)Cl-2{Ph2PCH2S(O)Ph-kappa P}] (2), with ligand L2 kappa P coordinated containing a pendent sulfinyl group, is the most active one (IC50 values of about 3 mu M), thus, with activities comparable to cisplatin. Complex 2 proved to have an even a higher antiproliferative activity than cisplatin against 8505C and SW480 cell lines, used as a model system of highly anaplastic cancers with low sensitivity to conventional chemotherapeutics such as cisplatin. Additional experiments demonstrated that apoptosis and autophagic cell death contribute to the drug's tumoricidal action. (C) 2013 Elsevier Masson SAS. All rights reserved.",
journal = "European Journal of Medicinal Chemistry",
title = "Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands",
number = "null",
volume = "69",
pages = "33-222",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_948"
}

Ludwig, G., Mijatović, S., Ranđelović, I., Bulatović, M. Z., Miljković, Đ., Maksimović-Ivanić, D., Korb, M., Lang, H., Steinborn, D.,& Kaluđerović, G. N.. (2013). Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands. in European Journal of Medicinal Chemistry, 69(null), 33-222.
https://hdl.handle.net/21.15107/rcub_ibiss_948

Ludwig G, Mijatović S, Ranđelović I, Bulatović MZ, Miljković Đ, Maksimović-Ivanić D, Korb M, Lang H, Steinborn D, Kaluđerović GN. Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands. in European Journal of Medicinal Chemistry. 2013;69(null):33-222.
https://hdl.handle.net/21.15107/rcub_ibiss_948 .

Ludwig, Gerd, Mijatović, Sanja, Ranđelović, Ivan, Bulatović, Mirna Z., Miljković, Đorđe, Maksimović-Ivanić, Danijela, Korb, Marcus, Lang, Heinrich, Steinborn, Dirk, Kaluđerović, Goran N., "Biological activity of neutral and cationic iridium(III) complexes with kappa P and kappa P,kappa S coordinated Ph2PCH2S(O)(x)Ph (x=0-2) ligands" in European Journal of Medicinal Chemistry, 69, no. null (2013):33-222,
https://hdl.handle.net/21.15107/rcub_ibiss_948 .

TY  - JOUR
AU  - Kaluđerović, Goran N.
AU  - Mijatović, Sanja
AU  - Zmejkovski, Bojana B
AU  - Bulatović, Mirna Z.
AU  - Gomez-Ruiz, Santiago
AU  - Mojić, Marija
AU  - Steinborn, Dirk
AU  - Miljković, Đorđe
AU  - Schmidt, Harry
AU  - Stošić-Grujičić, Stanislava
AU  - Sabo, Tibor J
AU  - Maksimović-Ivanić, Danijela
PY  - 2012
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/1223
AB  - Several new R(2)eddp (R = i-Pr, i-Bu; eddp = ethylenediamine-N,N'-di-3-propionate) esters and corresponding platinum(II) and platinum(IV) complexes of the general formula [PtCln(R(2)edda-type)] (n = 2, 4) were synthesized and characterized by spectroscopic methods (IR, H-1 and C-13 NMR) and elemental analysis. The crystal structure of platinum(IV) complex [PtCl4{(c-Pe)(2)eddip}] (3a) was resolved and is given herein. Ligand precursors, platinum(II), and platinum(IV) complexes were tested against eight tumor cell lines (CT26CL25, HTC116, SW620, PC3, LNCaP, U251, A375, and B16). Selectivity in the action of those compounds between tumor and two normal primary cells (fibroblasts and keratinocytes) are discussed. A structure-activity relationship of these compounds is discussed. Furthermore, cell cycle distribution, induction of necrosis, apoptosis, autophagy, anoikis, caspase activation, ROS, and RNS are presented on the cisplatin-resistant colon carcinoma HCT116 cell line.
T2  - Metallomics
T1  - Platinum(II/IV) complexes containing ethylenediamine-N,N '-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells
IS  - 9
VL  - 4
EP  - 987
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_1223
ER  - 

@article{
author = "Kaluđerović, Goran N. and Mijatović, Sanja and Zmejkovski, Bojana B and Bulatović, Mirna Z. and Gomez-Ruiz, Santiago and Mojić, Marija and Steinborn, Dirk and Miljković, Đorđe and Schmidt, Harry and Stošić-Grujičić, Stanislava and Sabo, Tibor J and Maksimović-Ivanić, Danijela",
year = "2012",
abstract = "Several new R(2)eddp (R = i-Pr, i-Bu; eddp = ethylenediamine-N,N'-di-3-propionate) esters and corresponding platinum(II) and platinum(IV) complexes of the general formula [PtCln(R(2)edda-type)] (n = 2, 4) were synthesized and characterized by spectroscopic methods (IR, H-1 and C-13 NMR) and elemental analysis. The crystal structure of platinum(IV) complex [PtCl4{(c-Pe)(2)eddip}] (3a) was resolved and is given herein. Ligand precursors, platinum(II), and platinum(IV) complexes were tested against eight tumor cell lines (CT26CL25, HTC116, SW620, PC3, LNCaP, U251, A375, and B16). Selectivity in the action of those compounds between tumor and two normal primary cells (fibroblasts and keratinocytes) are discussed. A structure-activity relationship of these compounds is discussed. Furthermore, cell cycle distribution, induction of necrosis, apoptosis, autophagy, anoikis, caspase activation, ROS, and RNS are presented on the cisplatin-resistant colon carcinoma HCT116 cell line.",
journal = "Metallomics",
title = "Platinum(II/IV) complexes containing ethylenediamine-N,N '-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells",
number = "9",
volume = "4",
pages = "987",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_1223"
}

Kaluđerović, G. N., Mijatović, S., Zmejkovski, B. B., Bulatović, M. Z., Gomez-Ruiz, S., Mojić, M., Steinborn, D., Miljković, Đ., Schmidt, H., Stošić-Grujičić, S., Sabo, T. J.,& Maksimović-Ivanić, D.. (2012). Platinum(II/IV) complexes containing ethylenediamine-N,N '-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells. in Metallomics, 4(9).
https://hdl.handle.net/21.15107/rcub_ibiss_1223

Kaluđerović GN, Mijatović S, Zmejkovski BB, Bulatović MZ, Gomez-Ruiz S, Mojić M, Steinborn D, Miljković Đ, Schmidt H, Stošić-Grujičić S, Sabo TJ, Maksimović-Ivanić D. Platinum(II/IV) complexes containing ethylenediamine-N,N '-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells. in Metallomics. 2012;4(9):null-987.
https://hdl.handle.net/21.15107/rcub_ibiss_1223 .

Kaluđerović, Goran N., Mijatović, Sanja, Zmejkovski, Bojana B, Bulatović, Mirna Z., Gomez-Ruiz, Santiago, Mojić, Marija, Steinborn, Dirk, Miljković, Đorđe, Schmidt, Harry, Stošić-Grujičić, Stanislava, Sabo, Tibor J, Maksimović-Ivanić, Danijela, "Platinum(II/IV) complexes containing ethylenediamine-N,N '-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells" in Metallomics, 4, no. 9 (2012),
https://hdl.handle.net/21.15107/rcub_ibiss_1223 .